NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $6.58 -0.12 (-1.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.56 -0.03 (-0.38%) As of 08/1/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lyra Therapeutics Stock (NASDAQ:LYRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$6.32▼$7.0650-Day Range$4.39▼$27.5852-Week Range$3.81▼$37.50Volume24,170 shsAverage Volume36,628 shsMarket Capitalization$8.75 millionP/E RatioN/ADividend YieldN/APrice Target$100.00Consensus RatingHold Company Overview Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Read More Lyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreLYRA MarketRank™: Lyra Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingLyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageLyra Therapeutics has received no research coverage in the past 90 days.Read more about Lyra Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyra Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.75% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 59.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.75% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 59.73%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Lyra Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows5 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,039.00 in company stock.Percentage Held by InsidersOnly 3.25% of the stock of Lyra Therapeutics is held by insiders.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LYRA Stock News HeadlinesLyra Therapeutics, Inc. (NASDAQ:LYRA) CEO Sells $13,944.15 in StockJuly 15, 2025 | insidertrades.comLyra Therapeutics Board Chair Waksal Steps DownAugust 2 at 12:04 PM | marketwatch.comAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.August 3 at 2:00 AM | The Oxford Club (Ad)Lyra Therapeutics Announces Leadership Changes in August 2025August 2 at 12:04 PM | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants - NasdaqJune 29, 2025 | nasdaq.comLyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%June 27, 2025 | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and WarrantsJune 27, 2025 | quiverquant.comQLyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesJune 27, 2025 | globenewswire.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $10.32 at the start of the year. Since then, LYRA shares have decreased by 36.2% and is now trading at $6.58. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings data on Tuesday, May, 6th. The company reported ($6.00) earnings per share for the quarter, topping the consensus estimate of ($7.50) by $1.50. The company earned $0.18 million during the quarter, compared to analyst estimates of $0.16 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 295.52% and a negative net margin of 6,711.39%. When did Lyra Therapeutics' stock split? Lyra Therapeutics shares reverse split on the morning of Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings5/06/2025Today8/03/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LYRA CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Lyra Therapeutics$100.00 High Price Target$100.00 Low Price Target$100.00 Potential Upside/Downside+1,419.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($60.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$93.43 million Net Margins-6,711.39% Pretax Margin-6,708.94% Return on Equity-295.52% Return on Assets-66.95% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual Sales$1.53 million Price / Sales5.72 Cash FlowN/A Price / Cash FlowN/A Book Value$8.86 per share Price / Book0.74Miscellaneous Outstanding Shares1,330,000Free Float1,282,000Market Cap$8.75 million OptionableOptionable Beta0.16 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LYRA) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.